GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » LT-Debt-to-Total-Asset

BioVaxys Technology (BioVaxys Technology) LT-Debt-to-Total-Asset : 0.00 (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioVaxys Technology's long-term debt to total assests ratio for the quarter that ended in Jul. 2023 was 0.00.

BioVaxys Technology's long-term debt to total assets ratio stayed the same from Jul. 2022 (0.00) to Jul. 2023 (0.00).


BioVaxys Technology LT-Debt-to-Total-Asset Historical Data

The historical data trend for BioVaxys Technology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology LT-Debt-to-Total-Asset Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
LT-Debt-to-Total-Asset
- - - - -

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioVaxys Technology LT-Debt-to-Total-Asset Calculation

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

LT Debt to Total Assets (A: Oct. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Oct. 2022 )/Total Assets (A: Oct. 2022 )
=0/0.633
=

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jul. 2023 is calculated as

LT Debt to Total Assets (Q: Jul. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jul. 2023 )/Total Assets (Q: Jul. 2023 )
=0/1.07
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology  (OTCPK:BVAXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


BioVaxys Technology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.

BioVaxys Technology (BioVaxys Technology) Headlines